All In Biotech

Drug Trial Radar · NCT06057922

A Study YL201 in Patients With Selected Advanced Solid Tumors

A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Selected Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

990

Planned (sponsor's estimate)

Start

Sep 22, 2023

Primary completion

Oct 2026

Study completion Oct 2028

Sponsor

Sponsor type
Industry
First posted
Sep 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors. The study will include 2 parts: Phase 1 dose expansion stage (Part 1) followed by a Phase 2 stage with expanded sample size (Part 2). Part 1 will estimate the RP2D in dose expansion cohorts of patients with not linited to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), esophageal squamous cell carcinoma (ESCC), metastatic castration-resistant prostate cancer (mCRPC), head and neck squamous cell carcinoma (HNSCC), sarcoma, ductal adenocarcinoma of pancreas (PDAC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), etc.. Part 2 will include patients with selected advanced solid tumor types enrolled at the RP2D to further assess the efficacy and safety of YL201.

Conditions

  • Advanced Solid Tumor

Interventions

  • YL201 for InjectionDrug

    Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle; and at dose levels of 1.0 mg/kg and 1.2 mg/kg administered on Days 1 and 8 of each Q3W treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the AEs as characterized by type, frequency, severity, timing, seriousness and relationship to study treatmentTime frame: By the global end of trial date, approximately within 36 months
  2. Evaluate the objective response rate (ORR) for patients with solid tumors which assessed using RECIST version 1.1Time frame: Time Frame: Approximately within 36 months
  3. Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancerTime frame: Time Frame: Approximately within 36 months

Locations

52 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of USTC

    Hefei, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Dongguan People's Hospital

    Dongguan, Guangdong, China

  • The Frist People's Hospital of Foshan

    Foshan, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China

  • Yuebei People's Hospital

    Shaoguan, Guangdong, China

  • The Fifth Affiliated Hospital Sun Yat-Sen University

    Zhuhai, Guangdong, China

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • Liuzhou Worker's Hospital

    Liuzhou, Guangxi, China

  • Affiliated Cancer Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China

  • Harbin Medical University Cancer Hospital

    Haerbin, Heilongjiang, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China

  • Affiliated Hospital of Jiangnan University

    Wuxi, Jiangsu, China

  • Jiangyin People's Hospital

    Wuxi, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, China

  • Jiangxi Cancer Hospital (Jiangxi Second People's Hospital)

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.